{"title":"A rare case of antidepressant discontinuation syndrome triggered by domperidone: Clinical insights and literature review.","authors":"Ashour Barkho, Bushra Elhusein, Niman Gajebasia","doi":"10.1177/2050313X251342973","DOIUrl":null,"url":null,"abstract":"<p><p>Antidepressant discontinuation syndrome is commonly observed among patients who abruptly discontinue or reduce the dosage of an antidepressant that has been administered for at least 6 weeks. Common manifestations may include flu-like symptoms, insomnia, nausea, impaired balance, sensory disturbances, headache, irritability, anxiety, and hyperarousal. These symptoms are typically mild, persist for 1-2 weeks, and resolve upon resumption of the medication. The probability of developing this syndrome increases with the prescribed pharmacological agent's prolonged treatment duration and shorter half-life. Before prescribing antidepressants, it is imperative to inform patients about the potential complications associated with the sudden discontinuation of the medication. Understanding this phenomenon can help prevent future incidents and reduce nonadherence risk. The majority of antidepressants possess the potential to induce antidepressant discontinuation syndrome. This case report presents a unique instance of discontinuation syndrome in a 50-year-old female patient with major depressive disorder who had been effectively managed on desvenlafaxine for several years. After initiating domperidone for chemotherapy-induced nausea, she experienced \"brain zaps\" and other symptoms consistent with antidepressant discontinuation syndrome. Upon cessation of domperidone, her symptoms rapidly resolved. This report examines potential interactions between domperidone and desvenlafaxine, emphasizing the necessity for clinicians to be cognizant of possible drug interactions that may precipitate discontinuation symptoms.</p>","PeriodicalId":21418,"journal":{"name":"SAGE Open Medical Case Reports","volume":"13 ","pages":"2050313X251342973"},"PeriodicalIF":0.6000,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12104596/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"SAGE Open Medical Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/2050313X251342973","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Antidepressant discontinuation syndrome is commonly observed among patients who abruptly discontinue or reduce the dosage of an antidepressant that has been administered for at least 6 weeks. Common manifestations may include flu-like symptoms, insomnia, nausea, impaired balance, sensory disturbances, headache, irritability, anxiety, and hyperarousal. These symptoms are typically mild, persist for 1-2 weeks, and resolve upon resumption of the medication. The probability of developing this syndrome increases with the prescribed pharmacological agent's prolonged treatment duration and shorter half-life. Before prescribing antidepressants, it is imperative to inform patients about the potential complications associated with the sudden discontinuation of the medication. Understanding this phenomenon can help prevent future incidents and reduce nonadherence risk. The majority of antidepressants possess the potential to induce antidepressant discontinuation syndrome. This case report presents a unique instance of discontinuation syndrome in a 50-year-old female patient with major depressive disorder who had been effectively managed on desvenlafaxine for several years. After initiating domperidone for chemotherapy-induced nausea, she experienced "brain zaps" and other symptoms consistent with antidepressant discontinuation syndrome. Upon cessation of domperidone, her symptoms rapidly resolved. This report examines potential interactions between domperidone and desvenlafaxine, emphasizing the necessity for clinicians to be cognizant of possible drug interactions that may precipitate discontinuation symptoms.
期刊介绍:
SAGE Open Medical Case Reports (indexed in PubMed Central) is a peer reviewed, open access journal. It aims to provide a publication home for short case reports and case series, which often do not find a place in traditional primary research journals, but provide key insights into real medical cases that are essential for physicians, and may ultimately help to improve patient outcomes. SAGE Open Medical Case Reports does not limit content due to page budgets or thematic significance. Papers are subject to rigorous peer review and are selected on the basis of whether the research is sound and deserves publication. By virtue of not restricting papers to a narrow discipline, SAGE Open Medical Case Reports facilitates the discovery of the connections between papers, whether within or between disciplines. Case reports can span the full spectrum of medicine across the health sciences in the broadest sense, including: Allergy/Immunology Anaesthesia/Pain Cardiovascular Critical Care/ Emergency Medicine Dentistry Dermatology Diabetes/Endocrinology Epidemiology/Public Health Gastroenterology/Hepatology Geriatrics/Gerontology Haematology Infectious Diseases Mental Health/Psychiatry Nephrology Neurology Nursing Obstetrics/Gynaecology Oncology Ophthalmology Orthopaedics/Rehabilitation/Occupational Therapy Otolaryngology Palliative Medicine Pathology Pharmacoeconomics/health economics Pharmacoepidemiology/Drug safety Psychopharmacology Radiology Respiratory Medicine Rheumatology/ Clinical Immunology Sports Medicine Surgery Toxicology Urology Women''s Health.